Scholarlink

Purpose <p>To analyze whether disease duration and severity can predict voice quality improvement following office-based blue laser therapy (OBLT) for benign lesions of the vocal folds.</p> Study design <p>Retrospective chart review.</p> Methods <p>Medical records of patients with benign lesions of the vocal folds who underwent OBLT between November 2023 and December 2025 were reviewed. Demographic data included age, gender, history of smoking, reflux disease, voice abuse, diagnosis, follow-up period, and disease duration. Self-perceived disease severity was assessed using the Voice Handicap Index-10 (VHI-10) and the Visual Analog Scale (VAS). Secondary outcome measures included acoustic and aerodynamic parameters.</p> Results <p>Sixty patients were included (35 females, mean age: 52.35 ± 14.45). The mean disease duration was 15.35 ± 20.80 months. Linear regression analysis showed no association between disease duration and mean change in VHI-10 (<i>r</i> = 0.018, <i>p</i> = 0.901) or VAS scores (<i>r</i> = 0.021, <i>p</i> = 0.886). There was a strong significant association between pre-operative VHI-10 score and mean change in VHI-10 (<i>r</i> = 0.681, <i>p</i> &lt; 0.001) and the mean change in VAS scores (<i>r</i> = 0.636, <i>p</i> &lt; 0.001), and between pre-operative VAS scores and mean change in VHI-10 (<i>r</i> = 0.642, <i>p</i> &lt; 0.001) and the mean change in VAS scores (<i>r</i> = 0.758, <i>p</i> &lt; 0.001). A weak positive significant association was found between pre-operative VAS scores and mean change in percent jitter (<i>r</i> = 0.271, <i>p</i> = 0.040). No significant associations were observed between disease duration, disease severity, and other acoustic or aerodynamic parameters.</p> Conclusion <p>Disease severity and not disease duration was associated with self-perceived improvement in voice quality following office-based blue laser therapy for benign vocal fold lesions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association between disease duration, severity, and treatment outcome of office-based blue laser therapy for benign vocal fold lesions

  • 期刊论文

  • 发表日期：

    2026年7月19日

查看全文
  • Abdul-Latif Hamdan,
  • Ghena Lababidi,
  • Lana Ghzayel,
  • Valerie Sarkis,
  • Patrick Abou Raji Feghali,
  • Ibana Carapiperis,
  • Elie Alam,
  • Marc Mourad,
  • Jerome R. Lechien

摘要

Purpose

To analyze whether disease duration and severity can predict voice quality improvement following office-based blue laser therapy (OBLT) for benign lesions of the vocal folds.

Study design

Retrospective chart review.

Methods

Medical records of patients with benign lesions of the vocal folds who underwent OBLT between November 2023 and December 2025 were reviewed. Demographic data included age, gender, history of smoking, reflux disease, voice abuse, diagnosis, follow-up period, and disease duration. Self-perceived disease severity was assessed using the Voice Handicap Index-10 (VHI-10) and the Visual Analog Scale (VAS). Secondary outcome measures included acoustic and aerodynamic parameters.

Results

Sixty patients were included (35 females, mean age: 52.35 ± 14.45). The mean disease duration was 15.35 ± 20.80 months. Linear regression analysis showed no association between disease duration and mean change in VHI-10 (r = 0.018, p = 0.901) or VAS scores (r = 0.021, p = 0.886). There was a strong significant association between pre-operative VHI-10 score and mean change in VHI-10 (r = 0.681, p < 0.001) and the mean change in VAS scores (r = 0.636, p < 0.001), and between pre-operative VAS scores and mean change in VHI-10 (r = 0.642, p < 0.001) and the mean change in VAS scores (r = 0.758, p < 0.001). A weak positive significant association was found between pre-operative VAS scores and mean change in percent jitter (r = 0.271, p = 0.040). No significant associations were observed between disease duration, disease severity, and other acoustic or aerodynamic parameters.

Conclusion

Disease severity and not disease duration was associated with self-perceived improvement in voice quality following office-based blue laser therapy for benign vocal fold lesions.